It's do-or-die time for the Aconex Ltd shorts

With the Aconex Ltd (ASX:ACX) results due out in the next few weeks, it's crunch time.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Planning software company Aconex Ltd (ASX: ACX) is one of the larger software companies on the ASX, with a $774 million market capitalisation.

It's also one of the most heavily short-sold. 12% of its total shares on issue are short-sold, which means that investors are betting heavily on the company's share price declining. The Aconex share price is down 52% for the year, and the upcoming full-year results could see either shareholders or short-sellers vindicated.

At the half-year results, Aconex reported international revenue growth of 11% overall, plus a big contribution from a recent acquisition, which gives the company a greater platform in Europe:

source: Company presentation

 

Ultimately an Aconex 'buy' hinges on the company's ability to continue to grow revenues, market share, and generate a 'network effect' where Aconex software becomes effectively the global industry standard. Should this happen, Aconex will likely prove a nicely profitable investment.

Short sellers are conversely betting that the company's software is not that good, and that it will fail to scale up its software over a reasonable time frame. Alternatively, they could also be betting simply that the company is overvalued given what it has achieved. Key things to watch will be revenue growth and customer acquisition, and we'll have full coverage of the results when Aconex reports in the next few weeks.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia owns shares of ACONEX FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »